{
    "id": 1798,
    "name": "pancreatic endocrine carcinoma",
    "source": "DOID",
    "definition": "An islet cell tumor that has_material_basis_in epithelial cells. [url:http\\://en.wikipedia.org/wiki/Carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:1798",
    "evidence": [
        {
            "id": 1933,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial that supported FDA approval, Sutent (sunitinib) demonstrated safety and improved progression free survival in patients with pancreatic neuroendocrine tumors (PMID: 21306237).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2401,
                    "pubMedId": 21306237,
                    "title": "Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21306237"
                },
                {
                    "id": 15581,
                    "pubMedId": null,
                    "title": "Sutent (sunitinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021938"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2523,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited pancreatic neuroendocrine tumor growth and invasion in transgenic mouse models (PMID: 22585997).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3247,
                    "pubMedId": 22585997,
                    "title": "Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22585997"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6008,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, BEZ235 was not well-tolerated and demonstrated modest anti-tumor activity in pancreatic neuroendocrine tumor patients who had progressed on Afinitor (everolimus), with a 51.6% (16/31) progression-free survival rate at 16 weeks (PMID: 26851029).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5229,
                    "pubMedId": 26851029,
                    "title": "A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26851029"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8960,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) induced tumor cell apoptosis, decreased microvessel density, inhibited tumor growth, and improved survival in transgenic mouse models of pancreatic neuroendocrine carcinoma (PMID: 26206868).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6808,
                    "pubMedId": 26206868,
                    "title": "Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206868"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18492,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a pancreatic neuroendocrine tumor harboring BRAF K601E demonstrated progressive disease when treated with Mekinist (trametinib) (PMID: 31158244).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16277,
                    "pubMedId": 31158244,
                    "title": "Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18505,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a pancreatic neuroendocrine tumor harboring BRAF K601E demonstrated progressive disease when treated with a combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (PMID: 31158244).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16277,
                    "pubMedId": 31158244,
                    "title": "Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18506,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic endocrine carcinoma found to harbor BRAF V600E demonstrated stable disease and some tumor shrinkage when treated with Zelboraf (vemurafenib) (PMID: 31158244).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16277,
                    "pubMedId": 31158244,
                    "title": "Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01466036",
            "title": "Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02077933",
            "title": "Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1384,
                    "therapyName": "Alpelisib + Everolimus",
                    "synonyms": null
                },
                {
                    "id": 1385,
                    "therapyName": "Alpelisib + Everolimus + Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101918",
            "title": "Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 624,
                    "therapyName": "Aflibercept",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02108782",
            "title": "Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 721,
                    "therapyName": "Dovitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02273752",
            "title": "Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315625",
            "title": "Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02575300",
            "title": "Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02893930",
            "title": "Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03043664",
            "title": "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6129,
                    "therapyName": "Lanreotide Depot + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03049189",
            "title": "Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8572,
                    "therapyName": "177Lu-edotreotide",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03074513",
            "title": "Atezolizumab and Bevacizumab in Rare Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03411915",
            "title": "A Study of XmAb18087 in Subjects With NET and GIST",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7309,
                    "therapyName": "XmAb18087",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03670030",
            "title": "A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3380,
                    "therapyName": "Nab-Rapamycin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03879694",
            "title": "Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8087,
                    "therapyName": "Octreotide + Sargramostim + SurVaxM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03891784",
            "title": "Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03901378",
            "title": "Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2604,
                    "therapyName": "Carboplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5145,
                    "therapyName": "Cisplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04123262",
            "title": "Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        }
    ]
}